沙格列汀与阿卡波糖治疗血糖控制不佳伴超重2型糖尿病患者的临床疗效比较

Clinical comparative reseach of saxagliptin and acarbose on poor- controlled type 2 diabetes with overweight

目的观察沙格列汀与阿卡波糖治疗血糖控制不佳伴超重的2型糖尿病患者的疗效、安全性。方法选取合并超重的初诊2型糖尿病患者80例,所有患者试验前在生活方式干预基础上给予二甲双胍联合胰岛素治疗,但血糖控制不佳(Hb A1c>7.5%)。所有患者随机分为沙格列汀组和阿卡波糖组各40例,均治疗12周,观察并记录2组患者治疗前后空腹血糖(FBG)、餐后2h血糖(PG2h)、糖化血红蛋白(Hb A1c)、胰岛素用量、低血糖发生率、不良反应发生率,肝肾功能变化情况。结果 2组治疗后FBG、2h PG、Hb A1c和胰岛素使用量均较治疗前下降,沙格列汀组下降程度高于阿卡波糖组,差异有统计学意义(P<0.05)。2组肝肾功能检查指标比较差异均无统计学意义(P>0.05)。结论沙格列汀对超重的2型糖尿病患者安全有效,可降低糖化血红蛋白水平,减少胰岛素用量。

Objective To investigate the clinical efficacy and safety of saxagliptin and acarbose treatment for poor-controlled type 2 diabetes mellitue（ T2DM） with overweight. Methods 80 cases T2 DM patients with overweight in our hospital were with golycemia pooly controlled（ glycosylated hemoglobin 〉7. 5%）,to whom metformin and insulin were given on lifestyle intervention before the test. All patients were randomly divided into saxagliptin group and acarbose group of 40 cases,were treated with saxagliptin and acarbose,Follow up for 12 weeks,and the fasting blood glucose（ FBS）,2 hours postprandial blood glucose（ PG2h）,glycosylated hemoglobin（ Hb A1c）,the incidence of hypoglycemia and adverse reaction,liver and kidney function were recorded. Results The FBG、PG2h、Hb A1 c and the dosage of insulin were reduced,and saxagliptin group was lower than acarbose group（ P〈0. 05）. The liver and kidney fuction of the two groups had no significant difference（ P〉0. 05）. Conclusion To T2 DM in overweight,Saxagliptin was safely and effectively,and also reduced Hb A1 c and the do-sage of insulin.